Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Bausch + Lomb

Status and phase: Completed; Phase 3

Conditions: Vitreous Hemorrhage; Diabetic Retinopathy

Treatments: Drug: Vitrase

Study type: Interventional

Funder types: Industry

Identifiers

NCT00198510

VIT-02-08961X

Details and patient eligibility

About

The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present >/= 1 month by history or exam
• BCVA is worse than 20/200 at time of screening

Exclusion criteria

• Corneal or lenticular abnormalities that preclude fundus observation
• Ongoing ocular infection, inflammation or history of herpetic corneal lesion
• Current or prior retinal detachment or retinal tears or breaks or intraocular tumor
• More than 1 severe vitreous hemorrhage within 6 months
• Previous vitrectomy for any reason
• Hemorrhage is exclusively pre-retinal, or old & organized
• Prior Vitrase for intravitreal injection in either eye
• No light perception in either eye at any time
• Known contraindications to study medication
• Sickle cell disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

750 participants in 2 patient groups

Vitrase

Experimental group

Description:

A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.

Treatment:

Drug: Vitrase

Drug: Vitrase

Drug: Vitrase

Observation

No Intervention group

Description:

Observation only, no medication or intravitreal injection